Cytek Biosciences, Inc. (CTKB)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 25/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 5.43% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Fund Divests Cytek Biosciences (CTKB) Following Revenue Slowdown and Declining Profitability
- Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool
- Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
- Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry
- Cytek’s (CTKB) Instruments Keep Selling While Losses Keep Growing
- Cytek Biosciences to Participate in Upcoming Investor Conferences
- Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
- Cytek (CTKB) Q2 2026 Earnings Call Transcript
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Cytek Biosciences, Inc..
Full CTKB Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.